2 completed, 1 terminated. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Ischemic Cardiomyopathy: new trials by email Literature Review of Ischemic Cardiomyopathy trials Research Report on Ischemic Cardiomyopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure. Allogeneic stem cells implantation - Heart Failure, Ischemic Cardiomyopathy | Phase 2 / Phase 3 | Terminated | AHEPA University Hospital | 1 | 2012-10-01 | 2022-07-25 |
| Ranolazine Implantable Cardioverter-Defibrillator Trial Ranolazine - Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy | Phase 3 | Completed | University of Rochester | 1012 | 2011-09-01 | 2018-08-27 |
| Study to Compare TWA Test and EPS Test for Predicting Patients at Risk for Life-threatening Heart Rhythms (ABCD Study) T-Wave Alternans test - Ischemic Cardiomyopathy, LV Dysfunction | Phase 3 | Completed | Abbott Medical Devices | 618 | 2001-04-01 | 2023-07-13 |
Heart Failure (2) · Coronary Artery Disease (1) · Death, Sudden (1) · Tachycardia, Ventricular (1) · Ventricular Dysfunction, Left (1) · Ventricular Fibrillation (1)
Cardiovascular Diseases (3) · Heart Diseases (3) · Arrhythmias, Cardiac (1) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Cardiac Conduction System Disease (1) · Coronary Disease (1) · Death (1) · Myocardial Ischemia (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Tachycardia (1) · Vascular Diseases (1) · Ventricular Dysfunction (1)
Ranolazine (1)
AHEPA University Hospital (1) · Abbott Medical Devices (1) · University of Rochester (1)
Canada (1) · Greece (1) · United States (1)
David Rosenbaum, MD (1) · Kyriakos Anastasiadis, MD, PhD, FETCS (1) · Otto Costantini, MD (1) · Wojciech Zareba, MD PhD (1)